NCT04627831View on ClinicalTrials.gov

Comparison of Captisol-Enabled™ Iohexol and Omnipaque™ in Patients With Impaired Renal Function Undergoing Coronary Angiography

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2022

Primary Completion Date

March 31, 2023

Study Completion Date

April 30, 2023

Conditions
Contrast-induced Nephropathy
Interventions
DRUG

CE-Iohexol

Captisol-Enabled™ Iohexol as needed for the diagnostic procedure. Volume will be determined according to medical need.

DRUG

Iohexol

Iohexol as needed for the diagnostic procedure. Volume will be determined according to medical need.

Sponsors
All Listed Sponsors
collaborator

CyDex Pharmaceuticals, Inc.

INDUSTRY

lead

Ligand Pharmaceuticals

INDUSTRY

NCT04627831 - Comparison of Captisol-Enabled™ Iohexol and Omnipaque™ in Patients With Impaired Renal Function Undergoing Coronary Angiography | Biotech Hunter | Biotech Hunter